2007
DOI: 10.1016/j.humimm.2007.02.004
|View full text |Cite
|
Sign up to set email alerts
|

The impact of human leukocyte antigen matching on transplant complications and immunosuppression dosage

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

1
6
0
2

Year Published

2008
2008
2021
2021

Publication Types

Select...
6
2
1

Relationship

0
9

Authors

Journals

citations
Cited by 23 publications
(9 citation statements)
references
References 36 publications
1
6
0
2
Order By: Relevance
“…Los genes que codifican para el sistema de antí-genos leucocitarios humanos (Human Leukocyte Antigen, HLA) son muy polimorfos y están asociados con un amplio número de funciones que van desde la presentación antigénica hasta la regulación de la reacción inmunitaria celular y humoral, por lo cual influyen de forma considerable en el reconocimiento alogénico en procedimientos de trasplante de órganos, en los cuales la compatibilidad del HLA tiene un papel fundamental (1)(2)(3)(4).…”
unclassified
“…Los genes que codifican para el sistema de antí-genos leucocitarios humanos (Human Leukocyte Antigen, HLA) son muy polimorfos y están asociados con un amplio número de funciones que van desde la presentación antigénica hasta la regulación de la reacción inmunitaria celular y humoral, por lo cual influyen de forma considerable en el reconocimiento alogénico en procedimientos de trasplante de órganos, en los cuales la compatibilidad del HLA tiene un papel fundamental (1)(2)(3)(4).…”
unclassified
“…Although the underlying pathophysiological processes and genetic underpinnings are incompletely understood, various factors have been identified that describe “immunological risk”, such as African American race, panel reactive antibody (PRA) level, previous transplantation, and human leukocyte antigen (HLA) mismatch. (2124) A predictive model developed with these variables is likely to achieve sufficient discrimination to form the basis of an informative risk-based analyses.…”
Section: Identification Of Risk Groups Of Patientsmentioning
confidence: 99%
“…A recent study of the USRDS database analyzing 23,443 patients transplanted between 1995 to 2002 revealed a mere 4%–8% lower use of immunosuppression with MMF and tacrolimus at 6 months in the “No HLA ABDR mismatch group” compared to the DR mismatch group, with no difference in the doses of CSA, sirolimus, or AZA between the two groups (17). All patients in the “No mismatch group” were on some form of immunosuppression with approximately 80% on a combination of an antimetabolite and calcineurin inhibitor, exposing them to potential nephrotoxicity.…”
Section: Need For Immunosuppression In Hla Identical Sibling Transplamentioning
confidence: 99%